Alx Oncology Holdings Inc (ALXO)
| Market Cap | 156.25M-38.3% |
| Revenue (ttm) | n/a |
| Net Income | -80.89M |
| EPS | -1.13 |
| Shares Out | 138.28M |
| PE Ratio | n/a |
| Forward PE | -2.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 764,235 |
| Open | 1.10 |
| Previous Close | 1.11 |
| Day's Range | 1.10 - 1.15 |
| 52-Week Range | 1.05 - 2.66 |
| Beta | 0.48 |
| Analysts | none |
| Price Target | 4.60(+307.08%) |
| Earnings Date | Nov 6, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ALXO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ALXO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ALXO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ALXO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ALXO Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Clinical and development costs | $7.09M | 59.81% |
| Personnel and related costs | $3.46M | 29.13% |
| Other research costs | $788.00K | 6.64% |
| Preclinical costs | $524.00K | 4.42% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ALXO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ALXO from public contracts
Source: USAspending.gov
ALXO Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ALXO’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score